Can epigenetic drugs prime prostate tumors for immune attack before surgery?

NCT ID NCT06888102

Recruiting now Disease control Sponsor: Edwin Posadas, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether giving epigenetic therapy before prostate removal can make the cancer more visible to the immune system. About 20 men with high-risk prostate cancer will receive the drugs before their scheduled prostatectomy. The main goals are to check safety, see if the treatment delays surgery, and measure changes in gene activity in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epigenetic therapy (drugs that change gene activity to help the immune system attack cancer)
What this could lead to: If it works, this could point toward a new way to make prostate cancer more sensitive to the immune system before surgery.
What could go wrong: This is a very early, small trial (20 men) focused on safety and feasibility, not effectiveness. The drugs may cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK PROSTATE CANCER

Contacts and locations

Locations

Cedars-Sinai Cancer at SOCC
RECRUITING

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.